Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Hydroquinone Proposal Should Prompt Industry Studies – Dermatologists

This article was originally published in The Tan Sheet

Executive Summary

Dermatologists concerned about losing over-the-counter access to skin bleaching products formulated with hydroquinone - as proposed by FDA - are counting on industry to submit compelling safety data

You may also be interested in...



Proposed Hydroquinone Ban Criticized In Literature Review

Disrupting the availability of hydroquinone skin-lightening products would represent an "overreaction" by FDA, according to a literature review published in the November issue of the Journal of the American Academy of Dermatology

Proposed Hydroquinone Ban Criticized In Literature Review

Disrupting the availability of hydroquinone skin-lightening products would represent an "overreaction" by FDA, according to a literature review published in the November issue of the Journal of the American Academy of Dermatology

FDA Pushes For Prescription-Only Sale Of Skin-Bleaching Products

FDA is proposing a rule that classifies all over-the-counter skin-bleaching products as drugs requiring an approved new drug application, the agency announced in a notice of proposed rulemaking published in an Aug. 29 Federal Register notice

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100136

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel